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Chemically related 4,5-linked aminoglycoside
antibiotics drive subunit rotation in opposite
directions
Michael R. Wasserman1, Arto Pulk2,3, Zhou Zhou1, Roger B. Altman1, John C. Zinder4, Keith D. Green5,
Sylvie Garneau-Tsodikova5, Jamie H. Doudna Cate2,3 & Scott C. Blanchard1,4

Dynamic remodelling of intersubunit bridge B2, a conserved RNA domain of the bacterial
ribosome connecting helices 44 (h44) and 69 (H69) of the small and large subunit,
respectively, impacts translation by controlling intersubunit rotation. Here we show that
aminoglycosides chemically related to neomycin—paromomycin, ribostamycin and
neamine—each bind to sites within h44 and H69 to perturb bridge B2 and affect subunit
rotation. Neomycin and paromomycin, which only differ by their ring-I 60 -polar group, drive
subunit rotation in opposite directions. This suggests that their distinct actions hinge on the
60 -substituent and the drug’s net positive charge. By solving the crystal structure of the
paromomycin–ribosome complex, we observe speciﬁc contacts between the apical tip of H69
and the 60 -hydroxyl on paromomycin from within the drug’s canonical h44-binding site.
These results indicate that aminoglycoside actions must be framed in the context of bridge B2
and their regulation of subunit rotation.
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A

odds with observations that bacterial strains harbouring errorprone ribosomes are viable23,24 and evidence that speciﬁc
aminoglycosides inhibit protein synthesis while exhibiting little,
to no, miscoding25. A comprehensive understanding of
aminoglycoside action on the ribosome must provide a
rationale for these observations, as well as data suggesting that
2-deoxystreptamine aminoglycosides may operate through more
than one functional site on the bacterial ribosome18,21,26.
Crystal structures of intact 70S Escherichia coli (E. coli)
ribosomes have recently revealed that aminoglycosides bind to
sites in both the small and large (50S) subunit of the bacterial
ribosome1,19,27. We have shown that neomycin, the most potent
and toxic member of the 4,5-linked aminoglycoside class21
(Fig. 1a), promotes translational miscoding and shutdown by
simultaneously binding to the h44-decoding site and the major
groove of H69 within the 30S and 50S subunits, respectively1
(Fig. 1b). These conserved rRNA elements, which comprise the
central intersubunit bridge B2, undergo marked structural
rearrangements during small-subunit rotation1, a process
underpinning multiple aspects of the translation cycle19,28–31. It
is not presently known whether, and to what extent, chemically
related 4,5-linked aminoglycosides within the neomycin class
impact the dynamics of subunit rotation.
Here, we present a detailed examination of structure–function
relationships in chemically related 4,5-linked aminoglycosides to
reveal that neomycin and paromomycin, which differ by only a
single functional group, bind h44 and H69 to drive subunit
rotation in opposite directions. These data, which include an
analysis of both ribosome- and drug-resistance mutations,
indicate that the distinct impacts of aminoglycosides on the
collective motions of bridge B2 play a central role in their
mechanisms of action. By solving the structure of the

minoglycoside antibiotics are potent, broad-spectrum
bactericidal agents that inhibit cell growth by targeting
functional centres within the bacterial ribosome to alter
global aspects of the translation mechanism1–5. However, despite
their clinical effectiveness, aminoglycosides are commonly
restricted to topical applications. Oral administration is
typically a last resort to ﬁght multi-drug-resistant pathogens
due to their propensities to elicit adverse side effects in patients,
including oto- and nephrotoxicities6. The molecular origins of
aminoglycoside toxicities and their bactericidal activities are
currently a matter of signiﬁcant debate.
Initiatives spanning the past half century indicate that
aminoglycosides with a 2-deoxystreptamine ring target the
conserved helix 44 (h44) messenger RNA (mRNA) ‘decoding
site’ region of ribosomal RNA (rRNA) within the small (30S)
subunit of the bacterial ribosome7,8, reducing translational ﬁdelity
by promoting the promiscuous incorporation of near- and noncognate aminoacyl-transfer RNAs (tRNAs) (miscoding)9,10.
Investigations of RNA oligonucleotide model systems2,
ribosomal subunits11 and intact ribosomes8,12–14 suggest that
aminoglycosides do so by binding the major groove of h44 to shift
the position and dynamics of two universally conserved residues
(A1492 and A1493) responsible for the recognition of the mRNA
codon-aminoacyl–tRNA (aa–tRNA) complex2,15.
While these investigations have greatly advanced our understanding of the molecular determinants of ribosome binding, they
fall short of elucidating how the aminoglycosides affect each stage
of the translation mechanism—initiation, elongation, termination
and recycling3,5,16–19. They are also unable to fully explain how
subtle chemical distinctions between structurally related
aminoglycosides give rise to unique inhibition and resistance
proﬁles20–22. Furthermore, a miscoding mechanism of action is at
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Figure 1 | Investigation of the neomycin family of aminoglycosides. (a) 4,5-linked 2-deoxystreptamine (2-DOS) aminoglycosides in the neomycin family.
(b) Overview of neomycin-binding sites in the small-subunit decoding site (h44, dark green) and in the large subunit H69 (light blue). 16S rRNA (30S) is
shown in blue, 23S rRNA (50S) in grey, P-site tRNA in green and mRNA in magenta. (c) Cartoon illustrating the ribosome labelling strategy used for
monitoring intersubunit rotation via single-molecule FRET, which has previously been shown to be affected by neomycin1. (d) Aminoglycoside-induced
inhibition of in vitro translation. IC50 values are indicated. Experiments were performed in triplicate and the mean±s.d. is plotted.
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paromomycin–ribosome complex to 3.1 Å resolution, we show
that such distinctions hinge on interactions of paromomycin with
the apical tip of H69 via its 60 -hydroxyl moiety from within its
canonical h44-binding site. These ﬁndings provide compelling
evidence that mechanisms describing the potency and selectivity
of this important class of anti-infective agents must include their
capacity to alter the dynamic properties of bridge B2 via
interactions with H69 of the large subunit.
Results
We investigated the structural and dynamic impacts of
4,5-linked aminoglycoside antibiotic (Fig. 1a) binding to bridge
B2 (Fig. 1b) within the intact E. coli 70S ribosome via singlemolecule FRET (smFRET) by site-speciﬁcally labelling ribosomal
proteins S13 and L1 within the small and large subunits with
donor and acceptor ﬂuorophores, respectively1 (Fig. 1c). To enable
quantitative smFRET measurements of subunit rotation
dynamics32–35, we employed intra-molecularly stabilized donor
and acceptor ﬂuorophores, which exhibit markedly enhanced
brightness and photostability36 (see the Methods section). Using
this system, smFRET data could be acquired at B2.6-fold faster
time resolution than previously reported at an improved signal-tonoise ratio, where a total of B500 photons could be detected for
each individual ribosome complex per imaging frame.
Coupled in vitro transcription–translation assays using puriﬁed
translation components (see Methods) showed that ribosomes
site-speciﬁcally labelled on proteins S13 and L1 were fully
functional in processive translation reactions (Supplementary
Fig. 1). This system was also employed to validate that neomycin
and the chemically related 4,5-linked aminoglycosides paromomycin, ribostamycin and neamine (Fig. 1a) inhibit the function of
our puriﬁed 70S E. coli ribosomes at concentrations consistent
with those reported using S30 or S100 extracts37,38. Notably,
neomycin and paromomycin exhibited roughly equivalent halfmaximal inhibitory concentration (IC50) values (14–20 nM),
whereas ribostamycin and neamine exhibited substantially
reduced potencies (130 and 1,400 nM, respectively) (Fig. 1d). At
face value, these data suggest that neomycin and paromomycin
operate through similar mechanisms, where rings III and IV
contribute as much as 100-fold to the overall afﬁnity of the drug–
ribosome interaction7,39.
Native ribosomes exhibit spontaneous subunit rotation. To
explore the impact of distinct 4,5-linked aminoglycosides on the
structure and dynamics of intact ribosomes, site-speciﬁcally
labelled 70S complexes bearing deacylated tRNAfMet in the
P-site were imaged in the absence and presence of speciﬁc concentrations of 4,5-linked aminoglycosides. Such complexes
spontaneously interconverted between high-FRET (0.67±0.01)
and low-FRET (0.26±0.01) states on the sub-second
timescale. Although these sites of labelling are in highly mobile
elements of the ribosome—the L1 stalk33,34,40–42 and head
domain43,44—dynamic FRET events principally reﬂect
reversible transitions between ‘rotated’/’hybrid’ and ‘unrotated’/
’classical’ ribosome conﬁgurations in which the S13 and L1
proteins are proximal and distal to each other, respectively1
(Figs 1c and 2a; Supplementary Fig. 2). This interpretation
was further corroborated by imaging the process of subunit
rotation from two distinct structural perspectives (Supplementary
Figs 3 and 4).
Hidden Markov modelling-based idealization45 of the S13–L1
data obtained using the QuB software package (see the Methods
section) also revealed evidence of a third, intermediate-FRET
(0.45±0.01) state that appeared to be on path between low- and
high-FRET conﬁgurations (Fig. 2a; Supplementary Fig. 5). The

existence and kinetic linkage of these FRET states was
corroborated by generating transition density plots from the
idealized data46, which revealed six well-deﬁned peaks
symmetrically distributed with respect to the diagonal axis
(Supplementary Fig. 5). Such ﬁndings suggest that at least one
transient intermediate state of subunit rotation is transited
on the path between unrotated and fully rotated ribosome
conﬁgurations1.
Steady-state actions of neomycin on intact 70S ribosomes.
Ribosome complexes bearing deacylated tRNAfMet in the P-site
exhibited a pronounced bimodal response to the addition of
neomycin1 (Fig. 2b; Supplementary Fig. 6a). Consistent with h44
binding1,18, low neomycin concentrations (up to 100 nM)
increased the occupancy of the low-FRET, unrotated ribosome
conﬁguration by B1.4- to 1.6-fold (Fig. 2b; Supplementary
Fig. 6a). The improved time resolution and signal-to-noise ratio
afforded by the use of intra-molecularly stabilized ﬂuorophores
also revealed that neomycin concomitantly stabilized the
intermediate-FRET state by B2.5-fold. At concentrations above
100 nM, the intermediate-FRET, partially rotated ribosome
conﬁguration was preferentially stabilized, accompanied by an
approximately ﬁvefold decrease in the global rate of intersubunit
dynamics (0.7 versus 4.9 s  1 or 5.4 s  1) (Fig. 2b). These effects
have been speciﬁcally attributed to neomycin’s interaction with
the major groove of H69, which blocks the axial compression of
H69 required for subunit rotation1. Hence, the predominant
impact of neomycin binding to both h44 and H69 is to destabilize
the unrotated ribosome conﬁguration in favour of intermediate
states of subunit rotation. Having established how ribosomes
quantitatively respond to neomycin, we next set out to examine
whether these changes in dynamics were altered by known drugresistance modiﬁcations.
Consistent with previous investigations of resistance
modiﬁcations to neomycin21,47, we observed increased IC50
values for both the ring-I-modiﬁed, 60 -N-acetyl-neomycin
(0.75 mM) and the ring II-modiﬁed 3-N-acetyl-neomycin
(34 mM) (Supplementary Fig. 7; Supplementary Table 1). In
agreement with the mode of interaction between neomycin and
the ribosome observed crystallographically1 in which rings I and
II of the drug recognize chemical features within the major
groove of both h44 and H69, subunit rotation dynamics were
only weakly affected (1.4–2-fold) by 60 -N-acetyl-neomycin and
largely unaffected by 3-N-acetyl-neomycin (see the Methods
section; Supplementary Fig. 8). 60 -N-acetyl-neomycin modestly
stabilized (twofold) both low- and intermediate-FRET states at
concentrations above 1 mM (Supplementary Fig. 8). By contrast,
3-N-acetyl-neomycin exhibited little, to no, detectable impact on
the FRET-state distribution even at the highest concentrations
tested (10 mM; Supplementary Fig. 8).
The contributions of rings III and IV of neomycin to the
observed impact on subunit rotation dynamics and processive
translation were examined through analogous investigations of
the closely related 4,5-linked aminoglycosides, ribostamycin
(rings I–III) and neamine (rings I and II) (Fig. 1a). Consistent
with previous literature7,20,37 and the crystallographically
observed modes of interaction of neomycin with h44 and H69
(ref. 1), both ribostamycin and neamine exhibited substantially
reduced impacts on subunit rotation dynamics and
correspondingly higher IC50 values in coupled in vitro
transcription–translation reactions (Supplementary Table 1). At
the highest concentrations tested (10 mM), both drugs elicited
low- and intermediate-FRET stabilization (Supplementary Fig. 6).
Collectively, these ﬁndings reveal that rings I and II are necessary
and sufﬁcient to mediate drug binding to h44 and H69.
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Figure 2 | Neomycin-induced effects on intersubunit rotation in wild-type and A1408G aminoglycoside-resistant ribosomes. (a) (Left) Single-molecule
ﬂuorescence (donor—green; acceptor—red) and FRET (blue) trajectories illustrating typical conformational changes in ribosomes labelled as shown in
Fig. 1c imaged in the absence of drug. FRET idealization is overlaid in red. (Right) A zoomed-in view highlights the transient nature of the intermediate-FRET
state. (b,c) (top panels) smFRET trajectories summed into FRET histograms reveal the population behaviours across a range of neomycin concentrations in
(b) wild-type and (c) A1408G ribosomes. (Bottom panels) Initial and ﬁnal FRET values for each transition summed into two-dimensional histograms
(transition density plots). Experiments were performed in triplicate on three separate days.

The h44- and H69-binding sites are functionally linked. Clinical isolates resistant to the 4,5-linked aminoglycosides exhibit
rRNA mutations that cluster in the h44-decoding site2. To
investigate the impact of an h44 mutation on drug binding to the
spatially separated h44- and H69-binding sites (Fig. 1b), identical
experiments were performed on ribosome complexes bearing an
A1408G point mutation that markedly reduces aminoglycoside
binding to h44 (refs 7,20) (Fig. 1b; see the Methods section) and
4

the IC50 of in vitro transcription–translation (42 versus 0.014 mM)
(Supplementary Fig. 7; Supplementary Table 1). Ribosomes
bearing the A1408G mutation exhibited globally similar
dynamic behaviours to wild-type ribosomes (Fig. 2b,c), and as
anticipated from reduced binding at the h44-decoding site, the
low-FRET, unrotated-state population did not increase in the
presence of neomycin (Fig. 2c). A modest increase in
intermediate-FRET state occupancy was evidenced only at
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elevated (41 mM) neomycin concentrations that correlated with
a global dampening of intersubunit rotation dynamics (Fig. 2c;
Supplementary Fig. 9a). These distinctions are consistent with a
functional linkage between the spatially separated neomycinbinding sites, where abrogation of drug binding at h44
concomitantly reduces the afﬁnity and/or accessibility of the
H69-binding site.

similarities and their nearly indistinguishable IC50’s for the wildtype ribosome (Fig. 1d), neomycin and paromomycin exhibit
unique sensitivities to resistance mutations in the decoding
site7,18,20–22. Such distinctions have been attributed to subtle
differences in their modes of interaction with speciﬁc bases within
the h44 major groove38. Consistent with earlier studies, we
observed that the A1408G mutation conferred substantially lower
levels of resistance to paromomycin (IC50 ¼ 1.6 mM) than for
neomycin (IC50 ¼ 42 mM) (Supplementary Fig. 7; Supplementary
Table 1).
Strikingly, and in line with its distinct impacts on the
translation mechanism21, paromomycin was observed to
preferentially stabilize the low-FRET, unrotated ribosome
conﬁguration at all concentrations tested (0.01–10 mM) (Fig. 3a;
Supplementary Fig. 6). At concentrations up to 1 mM, such effects
were notably correlated with a marked (B100%) increase in
subunit rotation dynamics (Fig. 3a, lower panels). Hence, despite

Paromomycin stabilizes an unrotated ribosome conﬁguration.
To gain a deeper understanding of the contribution of ring I to
4,5-linked aminoglycoside interactions with the intact ribosome,
we next set out to investigate the impact of paromomycin on
wild-type and A1408G ribosomes. Paromomycin differs chemically from neomycin at a single position on ring 1: in neomycin,
the 60 -position is a primary amine; in paromomycin, the
60 -position is a hydroxyl group (Fig. 1a). Despite their chemical
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Figure 3 | Paromomycin effects on intersubunit rotation in wild-type and A1408G aminoglycoside-resistant ribosomes. (a,b) (Top panels) smFRET
trajectories summed into FRET histograms reveal the population behaviours across a range of paromomycin concentrations in (a) wild-type and
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paromomycin’s close chemical relation, its impacts are starkly
opposite to those of neomycin. At concentrations above 1 mM,
however, evidence of a modest stabilization of the intermediateFRET state was observed; subunit rotation dynamics were also
suppressed (Fig. 3a; Supplementary Fig. 6). Ribosomes bearing
the A1408G mutation were largely unaffected by paromomycin
up to a concentration of 1 mM, above which clear evidence of lowand intermediate-FRET state stabilization emerged, together with
a concomitant dampening of intersubunit rotation dynamics
(Fig. 3b; Supplementary Fig. 9b). Such ﬁndings, together with
data obtained at lower pH (Supplementary Fig. 10), suggest that
paromomycin’s distinct impacts on subunit rotation hinge on
alterations in the drug’s interactions at both h44- and H69binding sites and that these changes arise via the 60 -hydroxyl
group and the drug’s net positive charge.
Paromomycin contacts H69 from within the h44-binding site.
To ascertain whether paromomycin’s distinct impacts on subunit
rotation dynamics stem from unique modes of interaction with
h44 and/or H69, we solved the crystal structure of the
paromomycin–70S ribosome complex at a resolution of 3.1 Å
(Table 1) under conditions enforcing drug protonation (below
neutral pH) and intermediate-FRET state stabilization1 (see the
Methods section; Supplementary Fig. 10). As observed for
neomycin1, unbiased Fobs  Fcalc difference electron density
maps revealed clear, positive electron density for paromomycin
in the major grooves of both h44 and H69. To a ﬁrst
approximation, paromomycin’s modes of interaction with both
sites appeared indistinguishable from those of neomycin (Fig. 4a),
corroborating the placement and orientation of both 4,5-linked

Table 1 | Data collection and reﬁnement statistics.
Data collection
Space group
Cell dimensions
a, b, c (Å)
Resolution (Å)*
CC1/2*
I/sI*
Rmeas*
Completeness (%)*
Redundancy*,w
Reﬁnement
Resolution (Å)
Number of reﬂections
Rwork/Rfree

P212121

212.10, 435.24, 614.44
70–3.1 (3.2–3.1)
99.6 (42.5)
6.53 (0.68)
17.8 (106.9)
86.3 (54.7)
4.9 (1.7)

70–3.0
909,645
0.2141/0.2816

Number of atoms
Protein/RNA
Ligand/ion
Water

291,292
848
1,729

B-factors
Protein/RNA
Ligand/ion
Water

64.3
61.6
62.3

R.m.s.d.
Bond lengths (Å)
Bond angles (°)
r.m.s.d., root mean squared deviation.
*Values in parentheses are for the highest-resolution shell.
wData were measured from 16 crystals.
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0.009
1.29

aminoglycosides within H69. The global conformations of both
the neomycin- and paromomycin-bound ribosome were also
indistinguishable. As observed for neomycin, and as suggested by
the intermediate-FRET state value observed in the presence of
both neomycin and paromomycin, the large and small subunits
adopt a partially rotated conﬁguration in which deacylated P-site
tRNA is bound in an intermediate hybrid state (P/pe)1 (Fig. 4b;
Supplementary Fig. 11).
However, one potentially critical distinction was observed
between the neomycin- and paromomycin-bound ribosome
crystal structures. In the presence of paromomycin, strong
electron density was observed for the universally conserved
A1913 residue located at the apical tip of the large subunit H69,
whereas this was not observed in the neomycin-bound structure
(Fig. 5a; Supplementary Fig. 12). These data suggest that the
A1913 residue remains dynamic when neomycin is bound1, but is
relatively static when paromomycin is bound. Inspection of the
paromomycin data revealed the 60 -hydroxyl moiety of the
h44-bound paromomycin molecule to be in hydrogen bonding
distance (B2.9 Å) of the A1913 Watson–Crick face (Fig. 5b). This
ﬁnding, together with the observation that subunit rotation
dynamics are largely unaffected by a 60 -deoxy-paromomycin
analogue48 (Supplementary Fig. 13), indicates that the contact
between the 60 -substituent in paromomycin and the apical tip of
H69 is a critical determinant that drives the preferential
stabilization of the unrotated ribosome conﬁguration. Given
that residue A1913 is observed to directly contact the anticodon
loop region of tRNA bound within the A-site-decoding
region13,49, the role of this contact on the aminoglycosideinduced miscoding mechanism warrants further exploration.
Discussion
Functional investigations aimed at quantifying the impact of
small-molecule inhibitors on the mechanism of protein synthesis
face signiﬁcant challenges when examined in the context of fulllength protein production. This is due to the fact that
mechanisms of action may be masked by additive or synergistic
effects on multiple steps of protein synthesis. Inhibition of
functional protein production may arise through impacts on any
aspect of the system including translation, transcription, protein
folding or by promoting protein inactivation or non-speciﬁc
aggregation. Our examination of the 4,5-linked aminoglycosides
in reconstituted protein translation reactions using puriﬁed
components revealed direct evidence of hidden and complex
modes of inhibition, as each of the 4,5-linked aminoglycosides
examined, with the exception of neamine, exhibited IC50 values
(14–130 nM) that were lower (2–18-fold) than the ribosome
concentration in the reaction (250 nM). Moreover, both neomycin and paromomycin were observed to exhibit nearly indistinguishable IC50 values (Fig. 1d; Supplementary Table 1) despite
their apparently distinct impacts on the dynamics of subunit
rotation (Figs 2 and 3). By contrast, isolated structural
investigations provide only snapshots of a drug’s impact on its
target. Indeed, our comparison of neomycin- and paromomycinbound ribosome structures revealed just a single obvious
distinction: the position and dynamics of residue A1913 (Fig. 5;
Supplementary Fig. 12). These ﬁndings provide a compelling
argument that single-molecule imaging methods offer a means to
bridge these distinct approaches to generate insights into dynamic
structural processes directly related to function.
The process of subunit rotation underpins essential aspects of
the translation mechanism and entails large-scale, functional
remodelling events within intersubunit bridge B2 (refs 1,31). In
line with cryo-electron microscopy investigations of the bacterial
ribosome50, we ﬁnd that the subunit rotation process is rapid and
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Figure 4 | Crystal structure of the paromomycin-bound partially rotated ribosome. (a) Paromomycin binding within the (left) h44-decoding site
and (right) within H69. 16S rRNA (blue), 23S rRNA H69 (grey) and paromomycin (h44—green; H69—teal) are shown, along with a (2Fobs  Fcalc) electron
density map, calculated in PHENIX and contoured at 1.4 s.d. from the mean. Paromomycin and H69 rRNA contacts o3.5 Å are shown as dashed lines.
(Inset) Paromomycin contacts within H69 are indistinguishable from those formed by neomycin (r.m.s.d. ¼ 0.412 Å). (b) Paromomycin induces
global rearrangements of the 70S ribosome that are indistinguishable from those stabilized by neomycin. (Inset) View of the 30S subunit from the
perspective of the 50S subunit. (Left) Difference in the vector shifts between equivalent RNA phosphorus atoms and protein Ca atoms in the unrotated
compared with the partially rotated paromomycin-bound ribosome; (middle) superposition of the partially rotated neomycin-bound and partially
rotated paromomycin-bound ribosomes. (Right) The fully rotated compared with the partially rotated paromomycin-bound ribosome. The vectors are
colour coded as indicated in the scale. Ribosomes were superimposed using the 50S subunit as the frame of reference. 30S head domain: H; 30S body:
B; 30S platform: P; 30S spur: Sp.

reversible under the present experimental conditions (ca. 5 s  1;
see the Methods section). We have leveraged this inherent
metastability and the synergies of smFRET and X-ray
crystallography to gain a deeper understanding of the actions of
chemically related aminoglycosides on the intact 70S ribosome.
These data reveal that both neomycin and paromomycin bind the
major grooves of both h44 and H69, central features of the bridge
B2 element. Drug binding at these structurally distinct,
functionally linked, sites impacts the nature and rate of
intersubunit rotation dynamics in opposing ways. Binding to
h44 stabilizes an unrotated ribosome conﬁguration, whereas drug
binding to H69 stabilizes an intermediate state of subunit
rotation. Simultaneous binding at both sites secures the
ribosome in an intermediate state of rotation that is
incompetent for basal translation elongation reactions1.
Together with the present investigations of chemically related
4,5-linked aminoglycosides and resistance modiﬁcations to both
neomycin and the ribosome, we conclude that binding at both the
h44 and H69 sites within bridge B2 contributes to the impact of
4,5-linked aminoglycoside antibiotics on protein synthesis.

The present observation of functional linkages between the
h44- and H69-binding sites is likely a natural consequence of the
collective conformational changes that occur within bridge B2
during subunit rotation. This conclusion warrants further
examination, particularly as it relates to aminoglycoside mechanisms of action and toxicity6,16. While h44 sequences vary
substantially between bacterial and human cells, the
corresponding sequences of H69 are more closely related51. The
extent of H69 sequence conservation and its functional role in the
process of subunit rotation may explain why some
aminoglycosides impinge upon the translation machinery of the
host cells and why aminoglycoside-resistance mutations have yet
to be reported within H69. Our own efforts to site-speciﬁcally
alter the H69 sequence to confer aminoglycoside resistance have
only led to modest reductions in neomycin binding when four
nucleotides in the helical region of H69 were swapped to the
corresponding human sequence. Notably, these mutations
imparted a marked increase in subunit rotation dynamics and
modestly stabilized the high-FRET, rotated ribosome
conﬁguration (Supplementary Fig. 14; see the Methods section).
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Figure 5 | Paromomycin contacts the universally conserved A1913
residue of H69 from its canonical h44 site of binding. (a) The decoding
site region of the paromomycin- (left) and neomycin- (right) bound
ribosome (unrotated) exhibit strong and weak electron density for residue
A1913 of H69, respectively. The 16S rRNA (blue), 23S rRNA (grey),
h44-bound paromomycin (green) and h44-bound neomycin (light blue) are
overlaid with feature-enhanced electron density maps69, calculated in
PHENIX and contoured at 1.4 s.d. from the mean. The temperature factors
for residue A1913 are as follows. Unrotated paromomycin-bound: B90 Å2;
unrotated neomycin-bound: B430 Å2. The lack of density for A1913 in the
neomycin-bound structure is highlighted with an asterisk. (b) Paromomycin
(green) bound within the canonical small-subunit h44-decoding site (blue)
contacts the apical tip of H69 via paromomycin ring I (60 -O) and the
universally conserved base A1913 (N6) of H69 (grey).

While more signiﬁcant H69 mutations may be expected to confer
greater aminoglycoside resistance, they are likely to be lethal
when made in isolation. To best address this issue, a
comprehensive, targeted screen for resistance mutations will
need to be performed taking into account the consideration that
bridge B2 exhibits collective conformational transitions that
regulate the nature and rate of intersubunit rotation.
A molecular rationale that explains how the A1408G-resistance
mutation in the h44-decoding site reduces the apparent impact of
aminoglycoside binding to H69 (Figs 2c and 3b; Supplementary
Fig. 9) is not immediately obvious. The insight provided by the
paromomycin-bound ribosome crystal structure, that aminoglycosides located within the h44 major groove can directly contact
the apical tip of H69, suggests that mutations that reduce h44
afﬁnity may simultaneously alter the local geometry of bridge B2
in a manner that indirectly affects drug interactions with the H69
major groove. A reduced afﬁnity for H69 may also arise from
global changes in the accessibility of the H69-binding site related
to compression of its major groove during subunit rotation1,31.
For instance, the H69-binding site is sterically occluded when the
ribosome adopts a fully rotated conﬁguration and may only be
optimally formed upon partial subunit rotation. In this view,
small changes in the underlying energy landscape of subunit
rotation may conformationally mask the H69 major groove by
altering the effective concentration of the transient H69-binding
8

site. Considerations of this kind may indeed contribute to
aminoglycoside resistance in eukaryotes, as the 80S ribosome
preferentially adopts rotated states52,53.
Preliminary efforts to examine kinetic features of neomycin
and paromomycin binding to the ribosome reveal that their onand off-rates to both h44 and H69 must also be taken into
consideration (Fig. 6). Neomycin rapidly and simultaneously
binds the major grooves of both h44 and H69 to stabilize the
partially rotated ribosome, whereas following buffer exchange, the
distribution of states exhibited resemble those observed in the
context of the A1408G mutation, in which residual binding at
H69 persists (Figs 2c and 6a). By contrast, paromomycin appears
to quickly bind (ca.o1 s) and preferentially stabilize the
unrotated ribosome conﬁguration while dissociating relatively
slowly from its h44-binding site upon buffer exchange (Fig. 6b).
These observations suggest that aminoglycosides reversibly bind
the h44-decoding site18, whereas binding may be more avid to
H69. Thus, distinct aminoglycoside actions in translation must
include considerations about the disparities in the kinetic
parameters of h44 and H69 binding. A quantitative
understanding of aminoglycoside actions on the ribosome
should therefore include considerations of the ribosome and
drug concentrations, the dynamics of subunit rotation and the
drug’s net charge. This latter point is particularly crucial, given
that the cell’s proton gradient has been reported to dissipate upon
aminoglycoside treatment16, an outcome that is expected to
increase the avidity of drug binding to bridge B2.
The capacity to image aminoglycoside activities on intact
ribosomes greatly extends our knowledge of the mechanisms of
action of speciﬁc aminoglycosides beyond that which could be
achieved using model oligonucleotide systems and offers a powerful
approach for exploring drug actions on deﬁned ribosome
complexes. However, the present investigations, together with
observations that conformational processes in the ribosome are
context dependent18, suggest that the impact of aminoglycosides
may be non-uniform in translation. Thus, targeted investigations
probing the many distinct ribosome complexes transited during
processive translation reactions must be further explored. A
complete understanding of aminoglycoside actions in the cell may
ultimately depend on the marriage of technological developments
affording increased imaging throughput with those providing global
snapshots of ribosome positions on speciﬁc mRNA species during
active translation54.
Methods
Reagents. Neomycin trisulfate salt hydrate (Sigma-Aldrich), paromomycin sulfate
salt (Sigma-Aldrich), ribostamycin sulfate salt (Sigma-Aldrich), neamine hydrochloride (Toronto Research Chemicals) and puromycin dihydrochloride (SigmaAldrich) were used at the purity stated by the commercial suppliers (Z97%).
Chemoenzymatic preparation of acetylated forms of neomycin is described below.
60 -deoxy-paromomycin pentaacetate salt was synthesized by the Vasella group
(ETH Zurich) as described48 and was a kind gift from David Crich (Wayne State
University). All smFRET experiments were performed in Tris-polymix buffer
(pH 7.5) containing 50 mM Tris acetate, pH 7.5, 5 mM Mg(OAc)2, 100 mM KCl,
5 mM NH4OAc, 0.5 mM CaCl2, 0.1 mM EDTA, 5 mM putrescine and 1 mM
spermidine.
Generation of site-speciﬁcally labelled ribosome complexes. 30S subunits
enzymatically labelled on S13 (N-Sfp) with LD550 (Lumidyne Technologies) and
50S subunits labelled with LD650 on L1 (T202C) were prepared and puriﬁed as
previously described1,40. To label ribosomal protein L5 on native ribosomes, L5 was
PCR cloned from E. coli strain K12 genomic DNA into the pPROEX HTb vector
with a TEV-protease-cleavable histidine (His)6 tag and a 12-residue peptide
encoding the A1 epitope for the AcpS phosphopantetheinyl transferase reaction55
(amino-acid sequence, GDSLDMLEWSLM) fused at the N terminus (N-AcpS).
After plasmid shufﬂing into an E. coli DL5 knockout strain56, cells were cultured
and ribosomes were harvested, cleaved and labelled in situ as performed for
S13-labelled subunits1. Cy5-fMet-tRNAfMet (Cy5-s4U8) was puriﬁed57 and
labelled58 as previously described.
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Figure 6 | Neomycin and paromomycin rinse off of h44 but not H69. Aminoglycoside real-time deliveries and rinse-outs were performed on wild-type
ribosomes. For both (a) neomycin and (b) paromomycin, ﬁve population FRET histograms are shown representing the chronological order of the
experiment. Left to right: (1) no drug; (2) real-time delivery of 10 mM aminoglycoside; (3) aminoglycoside equilibrium; (4) real-time rinse-out; (5) 90 s
following rinse-out.

The A1408G point mutation in h44 of 16S rRNA was introduced into in vivo
assembled ribosomes containing N-Sfp S13 using the previously described MS2 tag
protocol59 (pSpurMS2). Similarly, the H69 mutations (C1908G, C1909A, G1921U
and G1922C) in 23S rRNA were introduced into in vivo assembled DL1
ribosomes40 using the MS2 tag protocol59 (p278MS2). To form intact 70S ribosome
complexes, LD550-S13 30S and LD650-L1 50S subunits were heat activated at 42°
C for 10 min in Tris-polymix Mg2 þ buffer. Ribosomes were then initiated with
fMet-tRNAfMet as previously described60.

Acquisition and analysis of subunit rotation dynamics. smFRET experiments
were performed using a prism-based total internal reﬂection microscope45,60 at
25 °C. Ribosome complexes programmed with biotinylated mRNA and bearing
P-site fMet-tRNAfMet were surface immobilized via a biotin–streptavidin bridge
within polyethylene glycol (PEG)-passivated, streptavidin-coated quartz
microﬂuidic chambers45,60 and imaged in Tris-polymix buffer with 5 mM Mg2 þ ,
supplemented with an oxygen scavenging system61 and triplet-state quenching
compounds62 (1 mM cyclooctatetraene, 1 mM nitrobenzyl alcohol and 1 mM
Trolox). Prior to experiments, P-site fMet-tRNAfMet was deacylated by incubation
with 2 mM puromycin, a mimetic substrate of the peptidyltransferase centre that
liberates nascent peptide chains63, for 10 min at 25 °C in Tris-polymix buffer at pH
8.5. Aminoglycoside titrations were executed at pH 7.5, unless otherwise noted.
smFRET data were acquired by directly exciting the LD550 ﬂuorophore linked
to ribosomal protein S13 at 532 nm (LaserQuantum), while the LD550 and LD650
intensities were simultaneously recorded in Metamorph (Molecular Devices) at a
15-ms integration time. Using this approach, ﬂuorescence and FRET trajectories
could be obtained from hundreds of surface-immobilized, ﬂuorescently labelled
ribosome complexes simultaneously, where an average of 500 photons were
collected for each ribosome complex per image frame. FRET traces were calculated
as: FRET ¼ ILD650/(ILD550 þ ILD650), where ILD550 and ILD650 are the instantaneous
donor and acceptor ﬂuorescence intensities, respectively. FRETing molecules were
selected for analysis using custom-made analytical software implemented in
MATLAB (MathWorks) using the following criteria: a single catastrophic
photobleaching event, at least 8:1 signal-to-background-noise ratio and 6:1 signalto-signal-noise ratio, less than four donor ﬂuorophore blinking events, a
correlation coefﬁcient between donor/acceptor o0.5 and a lifetime of at least 50
frames (750 ms) in any FRET state Z0.15. FRET trajectories were idealized to a
four-state hidden Markov model (Supplementary Fig. 5) using the segmental

k-means algorithm45. Occupancies in each FRET state were calculated from the
idealized dwell times in each state divided by the total dwell time in all nonzero
FRET states, and were plotted in Origin (OriginLab).
Prior to the puromycin reaction, ribosome complexes bearing fMet-tRNAfMet in
the P-site predominantly (B80%) occupied a stable, low-FRET (0.26±0.01; meanﬁtted FRET value±s.d. of the Gaussian centre over three biological replicates) state
(Supplementary Fig. 2a). A battery of published biological controls1, together with
high-resolution ribosome structures1,31, suggest that this FRET value corresponds to
an ‘unrotated’/’classical’ ribosome conﬁguration in which the S13 and L1 proteins
are distal to each other (Fig. 1c). A small fraction (B20%) of ribosomes exhibited
high-FRET (0.67±0.01) (Supplementary Fig. 2a). This FRET value is consistent
with a ‘rotated’/’hybrid’ conﬁguration in which the S13–L1 inter-protein distance is
substantially reduced (B40 Å closer) (Fig. 1c). Consistent with this representing a
subpopulation of ribosomes bearing deacylated P-site tRNA, all ribosomes were
observed to exhibit a predominantly high-FRET state upon puromycin treatment
(Supplementary Fig. 2b). Visual inspection of individual ﬂuorescence and FRET
trajectories obtained from puromycin-released complexes revealed time-dependent,
anti-correlated ﬂuctuations in donor and acceptor ﬂuorescence intensities
corresponding to low- to high-FRET state transitions (Fig. 2a). Consistent with the
notion that P-site tRNA deacylation ‘unlocks’ the ribosome to enable the process of
subunit rotation42, ribosome complexes bearing deacylated tRNAfMet in the P-site
spontaneously interconverted between unrotated and rotated conﬁgurations on the
sub-second timescale. P-site tRNA deacylation increased the average transition rate
between all three FRET states by B50-fold (B4.9 versus B0.1 s  1)
(Supplementary Fig. 5e). These data indicate that the observed motions
predominantly report on transitions between unrotated, partially rotated and fully
rotated conﬁgurations of the ribosome, rather than fast independent motions of the
L1 stalk alone. Hence, we ﬁnd that the process of subunit rotation in native
ribosome complexes can occur at rates that are roughly an order of magnitude faster
than EF-G-catalysed translocation57 and the rates previously reported through
investigations of in vitro reconstituted ribosome particles32 or ribosomes hybridized
to ﬂuorescent oligonucleotides35. This metastability provided an ideal platform for
exploring whether and to what extent chemically related aminoglycosides impact
the ribosome’s energy landscape upon binding.

Aminoglycoside association and dissociation experiments. The neomycin and
paromomycin rinse-in/out experiments presented were performed using stopped-
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ﬂow instrumentation on ribosomes labelled at L1–S13 and imaged as above, except
the integration time was lowered to 40 ms to allow for a longer imaging window.
Puriﬁcation of 70S ribosomes for in vitro translation. Tight-coupled 70S
ribosomes of a homogenous rRNA sequence were puriﬁed from strain SQ171
(Quan S., Skovgaard O. and Squires C.L., unpublished results) expressing the wildtype or A1408G rrnB operon using a previously described protocol60 with a slight
modiﬁcation. Prior to storage, ribosomes were buffer exchanged into 20 mM
HEPES-KOH pH 7.8, 30 mM KCl, 10 mM Mg(OAc)2 and 1 mM TCEP-HCl using
a 100-kDa MWCO Microcon (Millipore), and 1 molar equivalent of puriﬁed E. coli
S1 protein was added. The ribosome/S1 mixture was then incubated at 37 °C for
10 min and cooled to 4 °C over B5 min. The solution was then exchanged into the
same buffer and concentrated to [70S]410 mM before ﬂash freezing and storing in
liquid nitrogen.
Construction of the DNA template for in vitro translation. The DNA template
used for in vitro protein synthesis reactions was a PCR product made by amplifying
the Photinus pyralis luciferase gene. The primers were designed such that a T7
promoter followed by a bacterial Shine–Dalgarno sequence was added prior to the
start codon and a T7 terminator sequence was added after the stop codon, as per
the manufacturer’s recommendations (New England BioLabs).The primer
sequences are listed below, where the ﬁreﬂy luciferase sequence (lower case letters),
the T7 promoter (underlined), the Shine–Dalgarno sequence (bold) and the stop
codon (italics) are indicated. Forward: 50 -GCGAATTAATACGACTCACTATAGG
GCTTAAGTATAAGGAGGAAAAAATatggaagacgccaaaaacat-30 . Reverse: 50 -AAA
CCCCTCCGTTTAGAGAGGGGTTATGCTAGTTAcacggcgatctttccgccct-30 . Prior
to use in coupled in vitro transcription–translation reactions, the PCR product was
puriﬁed using the QIAquick PCR Purﬁcation Kit (Qiagen) and resuspended in
0.5  TE buffer to a ﬁnal concentration of 50 ng ml  1.
In vitro protein synthesis reactions. Solution A and Factor Mix were purchased
from New England BioLabs as part of the PURExpress DRibosomes In Vitro
Protein Synthesis Kit. Individual reactions contained 2 ml Solution A, 0.6 ml Factor
Mix, 250 nM or 100 nM tight-coupled 70S ribosomes and 5 nM DNA template in a
total volume of 5 ml. For the IC50 experiments, 4 ml of a reaction mix lacking
aminoglycosides was added to 1 ml of aminoglycoside dilution in 0.2 ml thin-walled
tubes on ice. For the ribosome activity assay, 4.1 ml of reaction mix was added
to 0.9 ml of ribosomes or buffer on ice. Synthesis was initiated by incubation
at 37 °C in a thermocycler (95 °C top) and terminated after 30 min by lowering the
temperature to 4 °C for 10 min.
Luciferase activity assay. Luciferase activity was quantiﬁed using the Luciferase
Assay System (Promega). Fifty microlitre of luciferase assay reagent was added to
the completed reactions, which were then transferred to white 96-well plates
(Corning, 360 ml well volume) for luminescence quantiﬁcation by an Inﬁnite
M1000 Pro microplate reader (Tecan). To determine IC50 of aminoglycosides,
luciferase activity assays were performed in triplicate across a series of drug concentrations. A no-drug control (100% activity) was used to normalize luminescence
measurements. Activity percentages were then converted to percent inhibition by
subtraction from 100%. These values were then plotted on a semi-log scale versus
aminoglycoside concentrations. To estimate IC50 values, plots were ﬁt to the Hill
equation: (100  [aminoglycoside]n)/((IC50)n þ [aminoglycoside]n).
Chemoenzymatic preparation of 3- and 60 -N-acetyl-neomycin. The enzymes
used to generate the N-acetyl-neomycin derivatives, AAC(3)-IV and AAC(60 )/
APH(200 ) were puriﬁed as previously reported64. Reaction mixtures (5 ml) containing
trisulfate salt hydrate (5 mM, Sigma-Aldrich), acetyl coenzyme A lithium salt
(7.5 mM, Sigma-Aldrich), ammonium bicarbonate (pH 7.0, 50 mM) and appropriate
enzyme (0.1 mg ml  1 for AAC(60 )/APH(200 ) and 0.03 mg ml  1 for AAC(3)-IV) were
incubated with shaking at 37 °C (for AAC(60 )/APH(200 )) or 25 °C (for AAC(3)-IV).
The reaction progress was monitored by thin-layer chromatography (TLC) (Merck,
SiO2 gel 60 F254) using a 3:2/MeOH:NH4OH eluent system and staining with a
cerium-molybdate stain ((NH4)2Ce(NO3)6 (5 g), (NH4)6Mo7O244H2O (120 g),
H2SO4 (80 ml) and H2O (720 ml)). Reactions were generally complete after 24 h of
incubation. Once the enzymatic conversion was completed, the enzyme was
precipitated by addition of an equal volume (5 ml) of ice-cold MeOH. The mixture
was cooled at  20 °C for at least 10 min and centrifuged (5,500 r.p.m., 10 min, 4 °C,
Sorvall RC6 Plus centrifuge, rotor F21S-8x50) to pellet the protein. To extract any
N-acetylated neomycin that could be associated with the protein, the protein pellet
was resuspended in 1 ml of cold H2O, 1 ml of ice-cold MeOH was added and the
precipitation process was repeated two more times. The 14 ml of combined solvent
was removed in vacuo and the residue was resuspended in 1 ml of H2O. N-acetylated
neomycin products were puriﬁed away from the CoA side-product on an Amberlite
CG-50 (100–200 mesh: ammonium form, column packed ¼ 1  10 cm). The
residual solution was loaded onto the ion-exchange column and washed with 15 ml
H2O. The compounds were eluted stepwise (0.4% increments of 3 ml each for
AAC(60 )/APH(200 ) and 0.2% increments of 3 ml each for AAC(3)-IV) using a
gradient of NH4OH (0–2%). The size of each fraction collected was 1.5 ml. To
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facilitate loading of the fractions onto the TLC plate for visualization, the fractions
were diluted with 1.5 ml of MeOH. Fractions containing desired N-acetylated
neomycin, as determined by TLC, were combined and the solvent was removed in
vacuo. Both 60 -N-acetyl-neomycin and 3-N-acetyl-neomycin eluted between 0.4 and
0.8% NH4OH. Reactions yielded 13.1 mg of 3-N-acetyl-neomycin (80%) and 6.4 mg
of 60 -N-acetyl-neomycin (39%). Note: the yield of the 60 -N-acetyl-neomycin is lower
as it was utilized to optimize the puriﬁcation protocol.
Ribosome puriﬁcation for crystallization. Ribosome puriﬁcation from E. coli
strain MRE600 was prepared as previously described65. Ribosome complexes with
ribosome recycling factor (RRF) were made by incubating 2 mM ribosomes, 8 mM
mRNA (50 -GGCAAGGAGGUAAAAUUCUACAAA-30 Thermo Scientiﬁc) and
4 mM tRNAPhe for 15 min at 37 °C. Next, 8 mM RRF was added and incubated for
15 min at 37 °C. Ribosomes were crystallized at 18 °C using microbatch 96-well
plates and buffers containing 4.0–5.0% 2-methyl-2,4-pentanediol, 4.1–4.5% PEG
8000, 4.0 mM MgCl2, 380 mM NH4Cl, 5.7 mM putrescine, 5.0 mM spermidine,
10 mM Tris, 40 mM MES, pH 6.5–7.0 and 0.25 mM EDTA.
Data collection and processing. Ribosome crystals were stepwise cryo-protected
to the ﬁnal conditions containing 7.0% 2-methyl-2,4-pentanediol, 7.0% PEG 8000
and 24% PEG 400, pH 4.8, to allow cryo-cooling of the crystals to liquid nitrogen
temperatures. During the last cryo-protection step (PEG 400 24%), paromomycin
sulfate salt (Sigma-Aldrich) was added at a 200-mM concentration to the cryoprotection buffer, and crystals were incubated at 4 °C with paromomycin. After 2 h
of incubation, crystals were frozen with liquid nitrogen. Diffraction data were
measured from crystals cooled to 100 K using 0.1–0.3° oscillations at the Advanced
Light Source (beamlines 8.3.1 and 12.3.1), each of which is equipped with an ADSC
Q315 area detector. Data were reduced using XDS66, yielding the statistics shown
in Table 1.
Molecular replacement and structure reﬁnement. Molecular replacement and
structure reﬁnement was carried out in PHENIX67 platform, and previously
published/deposited coordinates of neomycin-bound ribosomes (PDB ID: 4GAQ
4GAR 4GAS 4GAU) were used as a reference model1. Neomycin molecules were
removed from the molecular replacement model to reduce possible model bias
during reﬁnement. Corrections to the resulting model were carried out in Coot68.
The resulting structural models were then reﬁned using rounds of manual
rebuilding in Coot. Electron density maps were generated from the PHENIX
output directly. RNA rebuilding concentrated on the tRNAs, H69 and h44
(neomycin-/paromomycin-binding sites) and paromomycin structures were
inserted and reﬁned using Coot and PHENIX. Paromomycin occupancies were
determined by matching paromomycin atomic displacement parameters to the
mean value of neighbouring rRNA, and then the group occupancy of each
paromomycin was reﬁned in PHENIX as previously described1. As with
neomycin1, additional paromomycin-binding sites were found near A482 (H24),
G551 (H25), G1157 (H41), U1240 (H46), A1858 (H68) and C2674 (H95) in 23S
rRNA, and near C658 (h22), G902 (h27) and U1420 (h44) in 16S rRNA. Maps
comparing bridge B2a in neomycin-bound (PDB ID 4V9C) and paromomycinbound ribosome structures used feature-enhanced maps generated by phenix.fem
in the PHENIX-1.9-1692 release, with default parameters plus the combined-omit
map algorithm69.
Superpositions. Superpositions were carried out in PyMOL using the ’pair_ﬁt’
command70. Disordered or ﬂexible regions of 23S rRNA were not used (for
example, the L1 stalk, the L7/L12 stalk, H38 and H69) in the superpositions.
Superpositions were performed using ribose C10 positions or phosphorus atoms in
nucleotides. The angles of rotation of the 30S subunit domains were calculated
essentially as described previously1,31. Angles given for the rotation of the head
domain were calculated from 30S subunit structures superimposed by means of
their platform domains. A rotation of 0° is deﬁned as centering the head domain
over the 30S P-site, as seen in the structure of the unrotated ribosome31.
Superpositions of P/P, P/pe and P/E tRNAs used the C10 atoms of nucleotides
31–39 in the anticodon stem loop31. The comparisons of tRNA bending angles
used the glycosidic bond of position 31 near the end of the anticodon stem loop
and the glycosidic bond of nucleotide 63 in superimposed tRNAs31. The calculated
bending angles were 24° for P/P tRNA compared with P/pe tRNA, and 14° for P/pe
tRNA compared with P/E tRNA. For the H69-bound neomycin and paromomycin
rRNA comparison, 23S rRNA positions 1906–1909, 1919–1931 were used.
Figure preparation. All structure ﬁgures were made using the program PyMOL70.
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